{
  "ticker": "NSB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02962793",
  "id": "02962793",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250627",
  "time": "0929",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250627/pdf/06l5ftngmx0ghm.pdf",
  "summary": "**Material Information Summary:**  \n\n- **Acquisition Completed**: NSB has acquired 100% of Isopogen WA, gaining full rights to the **StemSmart\u2122 patented stem cell technology**.  \n- **Funding**: Post-placement cash balance **~$7.5 million**.  \n- **Clinical Focus**: Immediate priority on **Special Access Program (SAP) for fistulising Crohn\u2019s disease**, targeting unmet medical need.  \n- **Clinical Data**:  \n  - **Phase 2 trial** in refractory Crohn\u2019s disease showed **promising efficacy/safety** (majority of 18 patients improved, many achieved remission).  \n  - Prior **Phase 1 trials** in steroid-refractory GVHD demonstrated **symptom resolution/survival improvement** (adults and children).  \n- **Market Potential**: Addressable markets include **Crohn\u2019s ($13.8B by 2026)**, **GVHD ($5.3B by 2032)**, and transplant/kidney/lung disorders.  \n- **Board Changes**: New non-executive directors appointed (*Robert McKenzie as Chair, Paul Fry*); options issued (5M each at $0.07, 3-year term).  \n- **Research Note**: No new capital raising or material financial terms disclosed; focus on pipeline advancement post-acquisition.  \n\n**Omitted**: Director quotes, historical trial details (referenced only), forward-looking statements.",
  "usage": {
    "prompt_tokens": 1689,
    "completion_tokens": 298,
    "total_tokens": 1987,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-26T23:41:45.231500"
}